Fennec Pharmaceuticals Inc.FENCNASDAQ

|||

Overview Charts News Fundamentals Key Metrics TTM Financials Earnings Growth Rating Analysts Institutional Peers Historical

Latest News

globenewswire.com

Southpoint holdings in Fennec Pharmaceuticals Inc. (TSX: FENC)

NEW YORK, Dec. 26, 2025 (GLOBE NEWSWIRE) -- Southpoint Capital Advisors LP (“Southpoint”), acting on behalf of certain Southpoint funds for which it serves as investment manager, announces that on December 24, 2025, pursuant to securities laws, it disposed of beneficial ownership of 1,000,000 common shares (a “Common Share”) of Fennec Pharmaceuticals Inc. (“Fennec”), representing approximately 2.93% of the outstanding Common Shares (calculated on a fully diluted basis).

defenseworld.net

Adherex Technologies Inc. (NASDAQ:FENC) Given Consensus Recommendation of “Hold” by Analysts

Adherex Technologies Inc. (NASDAQ: FENC - Get Free Report) has been given a consensus recommendation of "Hold" by the five brokerages that are covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and three have assigned a buy recommendation to the company. The

seekingalpha.com

Fennec Pharmaceuticals: A Compelling Single-Asset Growth Story For 2026

Fennec Pharmaceuticals is a commercial-stage oncology supportive-care company centered on Pedmark/Pedmarqsi. This drug helps reduce cisplatin-induced ototoxicity in pediatric patients who are battling cancer. Pedmark is FDA-approved for pediatric patients ≥1 month, and it has shown good efficacy so far with patients.

globenewswire.com

Fennec Pharmaceuticals Announces Investigator-Sponsored Trial to Be Conducted by City of Hope in Metastatic Testicular Germ Cell Tumors

– City of Hope to Evaluate PEDMARK ® for Reducing Ototoxicity in Adult Men with Stage II-III Metastatic Testicular Germ Cell Tumors –

feeds.benzinga.com

Pedmark Delivers In Japan Study — Less Hearing Loss, Same Cancer-Fighting Power

Pedmark cut cisplatin-related hearing loss in a Japan trial, with strong safety and no impact on tumor response, supporting plans for Japan registration.

globenewswire.com

Fennec Pharmaceuticals Announces Positive Topline Results From Investigator-Initiated Clinical Study of PEDMARK® in Japan to Reduce Cisplatin-Induced Hearing Loss

– Study, Which Enrolled 27 Patients, Met Primary Endpoint with a Significant Reduction in Hearing Loss in 3-18 Year Old Patients who Received PEDMARK ® when Compared with Historically Reported Rates of Hearing Loss in Patients Receiving Cisplatin Alone (16-24% versus 56-63%, Respectively) –

defenseworld.net

Brokerages Set Adherex Technologies Inc. (NASDAQ:FENC) Price Target at $13.33

Shares of Adherex Technologies Inc. (NASDAQ: FENC - Get Free Report) have been assigned a consensus recommendation of "Hold" from the five brokerages that are covering the firm, Marketbeat reports. Two investment analysts have rated the stock with a sell rating and three have assigned a buy rating to the company. The average twelve-month target price

globenewswire.com

Fennec Pharmaceuticals to Participate in Piper Sandler 37th Annual Healthcare Conference

RESEARCH TRIANGLE PARK, N.C., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on December 3, 2025 at 1:00 p.m. ET, which will be available via webcast.

globenewswire.com

Fennec Pharmaceuticals Announces Completion Of Full Debt Redemption

RESEARCH TRIANGLE PARK, N. C. , Nov. 19, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC) (TSX: FRX) ("Fennec" or the "Company"), a specialty pharmaceutical company, today announced it has repurchased and redeemed all of Fennec's outstanding convertible notes issued to Petrichor Opportunities Fund I LP and Petrichor Opportunities Fund I Intermediate LP using proceeds from the closing of the Company's previously announced underwritten public offering in the United States and concurrent private placement in Canada, closed on November 17 and 18, 2025, respectively.

globenewswire.com

Fennec Pharmaceuticals Announces Closing of Offering of Common Shares

RESEARCH TRIANGLE PARK, N.C., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) (“Fennec” or the “Company”), a specialty pharmaceutical company, today announced the closing of its underwritten registered public offering of 5,366,667 common shares (which amount includes exercise in full of the underwriters' option to purchase additional common shares) at a public offering price of $7.50 per share. Fennec's total gross proceeds from the offering (before deducting the underwriting discounts and offering expenses) are approximately $40,250,000.

globenewswire.com

Fennec Pharmaceuticals Announces Private Offering of Common Shares in Canada

RESEARCH TRIANGLE PARK, N.C., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) (“Fennec” or the “Company”), a specialty pharmaceutical company, today announced that it intends to engage in a non-brokered offering of its common shares in Canada, at a price of US$7.50 per share, with certain of its existing institutional shareholders, for aggregate gross proceeds of up to US$5,025,000. The offering is expected to close on November 17, 2025, subject to the Company entering into subscription agreements with investors in the offering, if any, and certain customary closing conditions including, but not limited to, the receipt of all necessary approvals, including approval from the Toronto Stock Exchange (“TSX”).

globenewswire.com

Fennec Pharmaceuticals Announces Pricing of Offering of Common Shares

RESEARCH TRIANGLE PARK, N.C., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) (“Fennec” or the “Company”), a specialty pharmaceutical company, today announced the pricing of its underwritten registered public offering of 4,666,667 common shares at a public offering price of $7.50 per share. In addition, Fennec has granted the underwriters a 30-day option to purchase up to an additional 700,000 common shares on the same terms and conditions. Fennec anticipates the total gross proceeds from the offering (before deducting the underwriting discounts and offering expenses) will be approximately $35,000,000, excluding any exercise of the underwriters' option to purchase additional shares. The offering is expected to close on November 17, 2025, subject to customary closing conditions.

zacks.com

Adherex Technologies Inc. (FENC) Reports Q3 Loss, Tops Revenue Estimates

Adherex Technologies Inc. (FENC) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to a loss of $0.21 per share a year ago.

globenewswire.com

Fennec Pharmaceuticals Announces Proposed Offering of Common Shares

RESEARCH TRIANGLE PARK, N.C., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) (“Fennec” or the “Company”), a specialty pharmaceutical company, today announced that it intends to offer and sell its common shares in an underwritten registered public offering. In addition, Fennec intends to grant the underwriters a 30-day option to purchase up to an additional 15% of its common shares sold in the public offering.